Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 34

Entrada Therapeutics enters Nasdaq

The Ohio State spinout has gone public in an upsized IPO sized at approximately $182m.

Nov 11, 2021

Plus puts the brakes on reverse takeover

Corporate-backed driverless truck technology developer Plus will no longer merge with the publicly listed Hennessy Capital Investment Corp V.

Nov 11, 2021

Daily Deal Round Up: November 10, 2021

Capgemini, Salesforce and ServiceNow helped visual commerce platform developer Threekit net $35m while Tencent led a $26m round for UGC management software provider Mod.io.

Nov 10, 2021

PharmEasy fishes for $842m in IPO

Multicorporate-backed online pharmacy operator API Holdings has filed for an offering that will not involve its shareholders selling their stakes.

Nov 10, 2021

Rivian motors to $11.9bn IPO

Amazon, Ford, Cox Enterprises, Abdul Latif Jameel and Sumitomo are all notching up exits, as the electric jeep producer priced the largest initial public offering of 2021.

Nov 10, 2021

DoorDash orders up $8.1bn Wolt acquisition

Prosus Ventures is set to exit the food and consumer goods delivery service in an all-stock deal which will boost DoorDash's international aspirations.

Nov 10, 2021

Daily Deal Round Up: November 9, 2021

DivcoWest, JLL and Allegion combined in a $60m round for workplace data platform developer VergeSense while Sanofi committed up to $60m to ocular therapeutics developer Gyroscope.

Nov 9, 2021

FiscalNote fixes $1.3bn reverse takeover

The regulatory information service counts SoftBank, Renren, Jipyong, The Economist Group and S&P Global as existing investors and will get a Nasdaq listing through the deal.

Nov 9, 2021

Daily Deal Round Up: November 8, 2021

Cox Enterprises led a $58m round for healthcare delivery software provider Enlace Health while Johnson & Johnson snapped up portfolio company OrthoSpin for almost $80m.

Nov 8, 2021

IO Biotech floats in $100m IPO

The Lundbeck and Novo-backed cancer therapy developer priced its shares at the bottom of their range in an upsized offering.

Nov 8, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here